Page 17 - AN-4-2

Advanced Neurology Lipid droplets and neurodegenerative disorders

doi: 10.1038/mp.2015.177 68. Cole NB, Murphy DD, Grider T, et al. Lipid droplet binding
and oligomerization properties of the Parkinson’s disease
58. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene protein alpha-synuclein. J Biol Chem. 2002;277(8):6344-6352.
dose of apolipoprotein E type 4 allele and the risk
of Alzheimer’s disease in late onset families. Science. doi: 10.1074/jbc.M108414200
1993;261(5123):921-923. 69. Vincent BM, Tardiff DF, Piotrowski JS, et al. Inhibiting
doi: 10.1126/science.8346443 stearoyl-CoA desaturase ameliorates alpha-synuclein
cytotoxicity. Cell Rep. 2018;25(10):2742-2754.e2731.
59. Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s
disease: From lipid transport to physiopathology and doi: 10.1016/j.celrep.2018.11.028
therapeutics. Front Neurosci. 2021;15:630502. 70. Ates G, Goldberg J, Currais A, Maher P. CMS121, a fatty
doi: 10.3389/fnins.2021.630502 acid synthase inhibitor, protects against excess lipid
peroxidation and inflammation and alleviates cognitive loss
60. Griseti E, Bello AA, Bieth E, et al. Molecular mechanisms of in a transgenic mouse model of Alzheimer’s disease. Redox
perilipin protein function in lipid droplet metabolism. FEBS Biol. 2020;36:101648.
Lett. 2024;598(10):1170-1198.
doi: 10.1016/j.redox.2020.101648
doi: 10.1002/1873-3468.14792
71. Li Y, Yang X, Peng L, et al. Role of seipin in human
61. Yin C, Ackermann S, Ma Z, et al. ApoE attenuates diseases and experimental animal models. Biomolecules.
unresolvable inflammation by complex formation with 2022;12(6):840.
activated C1q. Nat Med. 2019;25(3):496-506.
doi: 10.3390/biom12060840
doi: 10.1038/s41591-018-0336-8
72. Bernier F, Kuhara T, Xiao J. Probiotic bifidobacterium
62. Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 breve MCC1274 protects against oxidative stress and
function increases amyloid seeding but reduces plaque- neuronal lipid droplet formation via PLIN4 gene regulation.
associated ApoE. Nat Neurosci. 2019;22(2):191-204. Microorganisms. 2023;11(3):791.
doi: 10.1038/s41593-018-0296-9 doi: 10.3390/microorganisms11030791
63. Heneka MT. ApoE4 makes microglia trem(2)bling. Neuron. 73. Han X, Zhao S, Song H, et al. Kaempferol alleviates
2023;111(2):142-144. LD-mitochondrial damage by promoting autophagy:
doi: 10.1016/j.neuron.2022.12.032 Implications in Parkinson’s disease. Redox Biol.
2021;41:101911.
64. Qin Q, Wang M, Yin Y, Tang Y. The specific mechanism
of TREM2 regulation of synaptic clearance in Alzheimer’s doi: 10.1016/j.redox.2021.101911
disease. Front Immunol. 2022;13:845897. 74. Murphy SR, Chang CC, Dogbevia G, et al. Acat1 knockdown
doi: 10.3389/fimmu.2022.845897 gene therapy decreases amyloid-beta in a mouse model of
Alzheimer’s disease. Mol Ther. 2013;21(8):1497-1506.
65. Fanning S, Selkoe D, Dettmer U. Parkinson’s disease:
Proteinopathy or lipidopathy? NPJ Parkinsons Dis. 2020;6:3. doi: 10.1038/mt.2013.118
75. Hutter-Paier B, Huttunen HJ, Puglielli L, et al. The ACAT
doi: 10.1038/s41531-019-0103-7
inhibitor CP-113,818 markedly reduces amyloid pathology
66. Fanning S, Selkoe D, Dettmer U. Vesicle trafficking and in a mouse model of Alzheimer’s disease. Neuron.
lipid metabolism in synucleinopathy. Acta Neuropathol. 2004;44(2):227-238.
2021;141(4):491-510.
doi: 10.1016/j.neuron.2004.08.043
doi: 10.1007/s00401-020-02177-z
76. Huttunen HJ, Havas D, Peach C, et al. The acyl-coenzyme A:
67. Fanning S, Haque A, Imberdis T, et al. Lipidomic analysis cholesterol acyltransferase inhibitor CI-1011 reverses diffuse
of alpha-synuclein neurotoxicity identifies stearoyl CoA brain amyloid pathology in aged amyloid precursor protein
desaturase as a target for parkinson treatment. Mol Cell. transgenic mice. J Neuropathol Exp Neurol. 2010;69(8):
2019;73(5):1001-1014.e1008. 777-788.
doi: 10.1016/j.molcel.2018.11.028 doi: 10.1097/NEN.0b013e3181e77ed9

Volume 4 Issue 2 (2025) 11 doi: 10.36922/an.5060